- Home
- Heart Failure Online 2022 - Session 3.1 & 3.2: Quality of Life and Multi-disciplinary Care in HF
Heart Failure Online 2022 - Session 3.1 & 3.2: Quality of Life and Multi-disciplinary Care in HF
- Heart Failure
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Overview
Heart Failure Online (HFO) is a new innovative virtual event, that brings together a leading international faculty to create a rich, interactive experience to best inform the global heart failure community of the latest developments and advances in clinical practice.
With patient management and outcomes at its core, Course Director Prof Andrew Coats (President of the Heart Failure Association and Professor of Cardiology, University of Warwick, UK) leads an interactive programme of discussion, opinion and case studies focusing on the patient journey.
Disclosure
In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session ‘Heart Failure Online 2022 - Session 3.1 & 3.2: Quality of Life and Multi-disciplinary Care in HF'' is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Instructions to Participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
Learning Objectives
The overall programme, Heart Failure Online 2022, endeavours to best address the following learning objectives:
- Select foundational and advanced management strategies in complex patients
- Discuss the validity of using ejection fraction to determine optimal treatment strategies
- Assess the likely impact of health technology on future practice
- Identify the underlying causes of heart failure
- Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
- Assess the impact of the multidisciplinary team on heart failure outcomes
- Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| Patient Case Presentation | A Journey with Cancer, Heart Failure & QoL | 30 mins | Andrew JS Coats (Warwick, UK) |
| Presentation & Discussion | Quality of Life: What is it and Should There be More Emphasis QoL Outcomes in Clinical Trials? | 15 mins | Richard Hobbs (Oxford, UK) |
| Presentation & Discussion | Clinical Interventions to Improve Functional Capacity and QoL | 15 mins | Mikhail Kosiborod (Kansas, US) |
| Presentation & Discussion | The Future of ICD use in Ischaemic and Non-ischaemic HF | 20 mins | Cecilia Linde (Stockholm, SE) |
| Presentation & Discussion | Spotlight Session: The Changing Role of the Heart Team: What is the Future? | 20 mins | Martin R Cowie (London, UK) |
A Journey with Cancer, Heart Failure & QoL
Duration: 30 mins
Speakers: Andrew JS Coats (Warwick, UK)
Quality of Life: What is it and Should There be More Emphasis QoL Outcomes in Clinical Trials?
Duration: 15 mins
Speakers: Richard Hobbs (Oxford, UK)
Clinical Interventions to Improve Functional Capacity and QoL
Duration: 15 mins
Speakers: Mikhail Kosiborod (Kansas, US)
The Future of ICD use in Ischaemic and Non-ischaemic HF
Duration: 20 mins
Speakers: Cecilia Linde (Stockholm, SE)
Spotlight Session: The Changing Role of the Heart Team: What is the Future?
Duration: 20 mins
Speakers: Martin R Cowie (London, UK)
Related Courses
- 1.00
Published:
Learning objectives
- Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
- Select appropriate patients for advanced medical therapy
- Recall recent trial data for novel therapeutic approaches
- Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF
- 1.25
Published:
Learning objectives
- To identify high-risk patient features indicative of worsening Heart Failure (HF)
- Name validated tools for serial prognostic assessment and risk stratification
- Adopt the use of appropriate assessment tools during patient follow-up
- Recall rates of recurrent HF events and their associated healthcare costs in worsening HF patients
- Recall the clinical benefit of emerging treatments targeted to treating worsening HF
- Initiate available treatment for the tailored management of worsening HF
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
- 0.50
Published:
Learning objectives
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice
- Not accredited
Published:
Learning objectives
- Recall guideline recommendations for the use of NT-proBNP in heart failure
- Describe current practices in heart failure diagnosis and the impact on treatment outcomes
- Develop an optimised approach to the timely diagnosis and management of heart failure
- 2.00
Published:
Learning objectives
- Recall clinical evidence and guidelines for the management of CKD patients without diabetes
- Describe current gaps and barriers in evidence-based management for CKD without diabetes
- Apply evidence based-management strategies to a case study
- Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
- Not accredited
Published:
Learning objectives
- Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
- Apply latest guideline recommendations to patient cases
- Describe barriers preventing early initiation of GDMT
- Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
- Identify the importance of the nurse/cross-functional team
- Not accredited
Published:
Learning objectives
- Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
- Recognise barriers preventing the use of GDMT in current practice.
- Identify strategies needed to drive implementation of GDMT in clinical practice.
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists